Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients.

Abstract

This study investigated the efficacy of Zoladex depot 3.6 mg (goserelin acetate) during a 4-month treatment of infertile patients with uterine myomas of different size and location. The investigation comprised 30 patients aged 22-42 years, distributed into 2 groups regarding uterine and myoma volume. The first group included patients with uterine myomas less than 70 ml and uterus less than 300 ml. The second group included patients in whom these volumes exceeded the above mentioned values. Zoladex depot was administered every 28 days for 4 months with ultrasonographic follow-up of volume decrease, whereas patients with submucous myomas underwent control hysteroscopy. The obtained results point to efficacy of Zoladex in decreasing the volumes of both myomas and uterus by more than 50%, which correlates with literature data. Of particular interest is complete disappearance of myomas in about 60% of patients of the first group. Serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were followed-up prior to and during Zoladex therapy where multivariate variance analysis showed statistically significant differences. The side effects were recorded and are similar to those of other GnRH analogues.

• Authors: V Kopitović, M Bujas, N Fistes Topalski, M Pjević, D Ilić, A Kapamadzija, I Bujas
• Journal: Medicinski pregled (Med Pregl) 2001 Jul-Aug Vol. 54 Issue 7-8 Pg. 339-46 ISSN: 0025-8105 [Print] Serbia
• PMID: 11905182 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Drug Implants
• Goserelin

Topics

• Adult
• Antineoplastic Agents, Hormonal (adverse effects, therapeutic use)
• Drug Implants
• Female
• Goserelin (adverse effects, therapeutic use)
• Humans
• Infertility, Female (etiology)
• Leiomyoma (complications, drug therapy)
• Uterine Neoplasms (complications, drug therapy)